

*ee  
wcl*  
HER2 molecule] terminating about 8 amino acid residues upstream of the transmembrane portion of the HER2 molecule.


REMARKS

Following the entry of this amendment, independent claim 26 and claims 3, 5, 7 and 22 which depend thereon will be pending in the application. Claims 2, 9-21 and 24 have been cancelled without prejudice to file a continuing application directed thereto. In order to facilitate allowance of the application, claim 26 has been revised. Specification support for the amendment to claim 26 can be found on page 4, lines 6-8 and page 13, lines 9-10, for instance.

Applicants ask that the Examiner who is assigned to this case call the undersigned at (415) 225-1994 prior to issuance of the first Office Action in order to resolve any outstanding issues.

A copy of a document pursuant to 37 C.F.R. § 10.9(b) is attached as proof of the authorization of the undersigned to prosecute the above-mentioned application. The original of this document is on file in the Office of Enrollment and Discipline.

Respectfully submitted,  
GENENTECH, INC.

Date: 12/13/94 By:   
Wendy M. Lee

460 Pt. San Bruno Blvd.  
So. San Francisco, CA 94080-4990  
Phone: (415) 225-1994  
Fax: (415) 952-9881